<DOC>
	<DOCNO>NCT01570764</DOCNO>
	<brief_summary>By include study patient significant worsen lung volume / DLCO ( carbon monoxide diffuse capacity ) previous year , basis open retrospective study recently conduct , hope demonstrate strategy combine prednisone intravenous cyclophosphamide therapy accompany increase frequency stabilization / improvement lung volume / DLCO patient 12 month 15 % placebo prednisone cyclophosphamide 50 % cyclophosphamide prednisone.We also hope demonstrate significant decrease number patient excluded failure CYC arm compare placebo arm .</brief_summary>
	<brief_title>Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease</brief_title>
	<detailed_description>This randomized prospective multicenter study evaluate efficacy placebo cyclophosphamide combination prednisone treatment systemic sclerosis relate interstitial lung disease . Patients allocate , randomization two group receive corticosteroid : group patient receive placebo cyclophosphamide group patient treat cyclophosphamide . Cyclophosphamide administer IV dose 0.7 g / ( maximum 1200 mg ) every 4 week . In patient 65 creatinine clearance 30 ml / min dose reduce 0.6 g / m² . The duration treatment cyclophosphamide 12 month .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Age ≥ 18 year old Signed informed consent Patient systemic sclerosis fulfil ACR American college rheumatology ( Masi et al . 1980 ) and/or Leroy Medsger ( LeRoy Medsger 2001 ) diagnostics criteria worsen ILD ( interstitial lung disease ) identify high resolution chest CT scan worsening force vital capacity ( FVC ) and/or total lung capacity ( TLC ) ≥10 % and/or worsen DLCO ≥ 15 % compare value obtain within 3 18 month precede inclusion ( DLCO , absence pulmonary arterial hypertension upon echocardiography ) Smokers may include ( DLCO must perform least 72h stop tobacco intake ) . Patients pulmonary hypertension ( mean pulmonary arterial pressure &lt; 35 mmHg upon right heart catheterisation ) secondary hypoxia due pulmonary fibrosis also include study . Physical examination prior inclusion study ( result must give patient ) . Effective contraception woman childbearing age ( negative pregnancy test baseline ) Membership social security scheme Prednisone prescribe dose great 15 mg/d last 3 month . Scleroderma renal crisis acute critical limb ischemia within last 3 month , Left ventricular ejection fraction 40 % evaluated echocardiography . Out proportion pulmonary hypertension ( mean pulmonary artery pressure 35 mmHg upon right heart catheterization ) . CYC treatment last 12 month . Allergy , hypersensitivity document adverse event contraindication drug use study ( cyclophosphamide , Uromitexan , corticosteroid , domperidone ... ) Patients past history cancer within four year inclusion and/or history chemotherapy cancer within four year inclusion ( remission without disease activity four year ) Severe infection : sepsis , cellulitis , gangrene last three month Past history cystitis relate cyclophosphamide treatment Association another connective disease : systemic lupus erythematosus , syndrome GougerotSjögren antiSSA/SSB , mixed connective tissue disease Patient pregnant , lactate use contraception consider effective investigator ( abstinence / oral contraception mechanical ) Patient childbearing , refuse contraception Failure sign inform consent unable consentPatient participate another clinical trial Injection Rituximab within 6 month precede inclusion Methotrexate Cellcept treatment inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Systemic sclerosis</keyword>
	<keyword>Interstitial lung disease</keyword>
	<keyword>Worsening</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Intravenous</keyword>
</DOC>